Aytu BioPharma Q4 FY26 net loss narrows to USD 15,000; revenue rises 6.4% to USD 16.1 million vs Q4 FY25
I'm LongbridgeAI, I can summarize articles.Aytu BioPharma reported Q4 FY26 net revenue of $16.1 million, a 6.4% increase year-over-year, driven by EXXUA's first full quarter of launch generating $3.94 million. Net loss narrowed significantly to $15,000 from $19.82 million in the prior year period. However, full-year results showed a 13.3% revenue decline to $57.6 million and a widened net loss of $14.25 million. CEO Josh Disbrow noted that Q4 prescriptions exceeded 3,300, more than doubling sequentially.
- Aytu Biopharma reported Q4 fiscal 2026 net revenue rose 6.4% to USD 16.1 million versus the year-ago quarter. * Net loss narrowed to USD 15,000, versus USD 19.82 million a year earlier. * Full-year net revenue fell 13.3% to USD 57.6 million, and net loss widened to USD 14.25 million. * EXXUA produced USD 3.94 million of Q4 net revenue, its first full quarter of launch, and USD 6.57 million for the year. * CEO Josh Disbrow said Q4 prescriptions topped 3,300, more than doubled sequentially, while June reached a record 1,261 scripts. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609221605ACCESSWRNAPR_____1223174) on September 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)